Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile

Translated title of the contribution: Levetiracetam in the treatment of juvenile myoclonic epilepsy

G. Boero, N. Specchio, A. Gambardella, A. T. Giallonardo, R. Michelucci, J. Fattouch, C. Di Bonaventura, A. La Neve, L. M. Specchio

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.

Translated title of the contributionLevetiracetam in the treatment of juvenile myoclonic epilepsy
Original languageItalian
Pages (from-to)101-103
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number129-130
Publication statusPublished - 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Levetiracetam in the treatment of juvenile myoclonic epilepsy'. Together they form a unique fingerprint.

Cite this